Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension

Alnylam Pharmaceuticals announced new interim results from an exploratory data analysis evaluating its Onpattro (patisiran). Onpattro was tested in APOLLO-B Phase III trial open-label extension period in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.